SynAct Pharma Starts Phase 2 Dengue Trial of Resomelagon in Brazil

SynAct Pharma AB ( (SE:SYNACT) ) has issued an update.

SynAct Pharma has begun dosing patients in its Phase 2 RESOVIR-2 trial, a randomized, placebo-controlled study evaluating oral resomelagon as an add-on therapy in 120 patients with symptomatic Dengue infection in Brazil. The study will assess time to disease resolution and the potential to reduce warning signs and severe Dengue, with recruitment tied to the current epidemic cycle and topline data expected in the third quarter of 2026.

By extending resomelagon’s clinical evaluation from COVID-19 into Dengue, SynAct aims to strengthen its position in host-directed therapies for severe viral infections, addressing a major unmet need where current treatment is largely limited to supportive care. Positive outcomes from RESOVIR-2 could provide additional proof-of-concept for resomelagon’s inflammation-resolving mechanism, potentially enhancing SynAct’s clinical credibility and strategic value in the anti-inflammatory and infectious disease markets.

The most recent analyst rating on (SE:SYNACT) stock is a Hold with a SEK22.00 price target. To see the full list of analyst forecasts on SynAct Pharma AB stock, see the SE:SYNACT Stock Forecast page.

More about SynAct Pharma AB

SynAct Pharma AB is a clinical-stage biotechnology company listed on Nasdaq Stockholm that focuses on resolving inflammation by selectively activating the melanocortin system. Its portfolio comprises oral and injectable melanocortin agonists designed to induce anti-inflammatory and pro-resolving effects, targeting patients with inflammatory conditions who need improved immune balance and better control of disease progression.

Average Trading Volume: 180,897

Technical Sentiment Signal: Sell

Current Market Cap: SEK923.7M

Learn more about SYNACT stock on TipRanks’ Stock Analysis page.